Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy
- 1 December 2017
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 268, 159-165
Abstract
No abstract availableKeywords
Funding Information
- NIH/NIGMS-sponsored Cell and Tissue Engineering (CTEng) Biotechnology Training Program (T32GM008433)
- National Science Foundation (DGE-1148903)
- Scientific and Technological Research Council of Turkey (TUBITAK) (B.14.2.TBT.0.06.01-219-19961)
This publication has 41 references indexed in Scilit:
- Orally Inhaled Dihydroergotamine: A ReviewHeadache: The Journal of Head and Face Pain, 2013
- Rapid kinetics to peak serum antibodies is achieved following influenza vaccination by dry-coated densely packed microprojections to skinJournal of Controlled Release, 2012
- Water Soluble Polymers for Pharmaceutical ApplicationsPolymers, 2011
- Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?Expert Opinion on Pharmacotherapy, 2010
- New acute treatments for headacheNeurological Sciences, 2010
- Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safetyDrug Delivery, 2010
- The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future ResearchMayo Clinic Proceedings, 2009
- Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of LifeMayo Clinic Proceedings, 2009
- Effect of Microneedle Design on Pain in Human VolunteersThe Clinical Journal of Pain, 2008
- DHE in the Pharmacotherapy of Migraine: Potential for a Larger RoleHeadache: The Journal of Head and Face Pain, 2006